Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $300,000.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 240,032 shares of the company’s stock, valued at $2,880,384. The transaction was disclosed in a filing with the SEC, which is available through this link.

Thomas Gad also recently made the following trade(s):

• On Thursday, May 23rd, Thomas Gad sold 7,351 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $13.00, for a total value of $95,563.00.

Y-mAbs Therapeutics Trading Down 1.5 %

Y-mAbs Therapeutics stock opened at $12.22 on Friday. Y-mAbs Therapeutics, Inc. has a 1 year low of $4.60 and a 1 year high of $20.90. The firm’s 50 day moving average price is $14.61 and its 200-day moving average price is $11.72.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.17. The company had revenue of $23.36 million for the quarter, compared to the consensus estimate of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. On average, equities analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.45 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on YMAB shares. Wedbush reissued an “outperform” rating and issued a $18.00 target price (up from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. HC Wainwright increased their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. Canaccord Genuity Group lifted their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, BMO Capital Markets increased their price target on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.33.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several large investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. boosted its stake in Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after buying an additional 1,056 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Y-mAbs Therapeutics by 4.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock worth $178,000 after acquiring an additional 1,089 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after acquiring an additional 1,657 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Y-mAbs Therapeutics by 17.5% in the fourth quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock valued at $147,000 after purchasing an additional 3,210 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Y-mAbs Therapeutics by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock worth $136,000 after purchasing an additional 3,340 shares during the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.